The RATIONALE 305 study demonstrated the efficacy of tislelizumab in combination with CTH as a first-line treatment for GC/GEJ, resulting in an OS of 17.2 months compared to 12.6 months in the placebo plus CTH group [167,175]. This evidence concerns the gene CTH and gastric cancer.